Boston Scientific Corporation recently presented new data on its FARAPULSE™ Pulsed Field Ablation (PFA) System and WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device at the AF Symposium 2025, highlighting their potential to improve outcomes for patients with atrial fibrillation (AF).

The ADVANTAGE AF clinical trial focused on using the FARAPULSE PFA System for both pulmonary vein isolation (PVI) and posterior wall ablation (PWA) in patients with persistent AF. This type of AF involves a prolonged irregular heartbeat, lasting more than seven days. The study involved 260 patients from 43 global sites who were intolerant to at least one anti-arrhythmic drug.

The key findings from the trial, after 12 months, included:

• A 2.3% rate of serious adverse events, meeting the primary safety endpoint.
• A primary effectiveness endpoint showing 63.5% of patients were free from AF, atrial flutter, or atrial tachycardia without needing re-ablation or increased medication.
• A high symptomatic AF recurrence-free rate of 85.3%, which increased to 91.8% among experienced physicians performing three or more procedures.
• No major complications such as stroke, pulmonary vein stenosis, or atrio-esophageal fistula were reported.

The study underscores the growing role of PFA as a treatment option for patients with persistent AF, offering positive safety and efficacy outcomes. Many patients were able to stop taking anti-arrhythmic drugs and reported improvements in quality of life.

Additionally, the OPTION trial sub-analysis further supported the effectiveness of the WATCHMAN FLX device for stroke prevention. The sub-analysis, based on data from 1,600 patients who had either concomitant or sequential implantation of the device following ablation, demonstrated that:

• Concomitant implantation resulted in a 44% reduction in non-procedural bleeding compared to oral anticoagulation (OAC) after 36 months (8.0% vs. 13.3%).
• Sequential implantation showed a 62% reduction in non-procedural bleeding (8.8% vs. 21.5%).
• Stroke rates were similar between the WATCHMAN FLX device and OAC, regardless of implantation method.

These studies reinforce the role of the FARAPULSE PFA System and the WATCHMAN FLX device in improving long-term outcomes for patients with atrial fibrillation, positioning them as key technologies in the management of the condition. The findings will continue to inform Boston Scientific's development of treatments aimed at expanding the number of patients who can benefit from these therapies.

 

 

Source: prnewswire.com

Report Abuse